शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
BSEMEDI-CAPS LTD.· Pharmaceuticals & BiotechnologyHighNeutral
Announced Thu, 6 Aug, 2026 · 17:07 IST

Medi-Caps re-appoints CMD; daughter-in-law and new CFO join board

Promoter Family Board EntryManagement Changes View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-2.1%Reaction day
₹26.55
prior close
—
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.0%-2.1% vs market
Pharmaceuticals peers, median of 168sector+0.3%-2.4% vs sector

On the reaction day the stock moved 2.1 pts less than Nifty Microcap 250 and 2.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
—
10m
—
15m
—
30m
—
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-2.1+0.0-2.1+0.3-2.4
Next day
+1.2-0.0+1.3+0.7+0.5
2d
-0.6-0.2-0.4+0.6-1.2
3d
+0.9+0.2+0.8+0.4+0.6
4d
-0.9+0.3-1.2+1.2-2.1
5d
+3.4+0.4+3.0+0.2+3.2
1w
—+0.9—+0.2—
15d
—+1.6—+1.1—
1m
—+2.0—+2.4—
2m
—+0.6—+1.6—
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 168Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Medi-Caps re-appointed Mr. Alok K. Garg as Chairman cum Managing Director for 3 years (1 Sept 2026 to 31 Aug 2029). Mr. Akshit Garg appointed as CFO and KMP from 7 Aug 2026. Mrs. Saloni Garg, daughter-in-law of the CMD, appointed as Additional Director and Whole-time Woman Director for 3 years. All director appointments need shareholder approval at the AGM.

Likely market impact

Daughter-in-law joining board signals family succession at promoter-led firm. Leadership continuity with CMD re-appointment likely neutral for stock.